

Supporting Information for

Ruthenium-Catalyzed Cycloaddition of Alkynes and Organic Azides

Li Zhang,[†] Xinguo Chen,[†] Peng Xue,[†] Herman H. Y. Sun,[†] Ian D. Williams,[†]

K. Barry Sharpless[‡], Valery V. Fokin^{‡,*} and Guochen Jia^{†,*}


[†]*Department of Chemistry, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong, and* [‡]*Department of Chemistry and the Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, California 92037, USA*

Experimental procedures

Reactions 1-7 were carried out under nitrogen atmosphere using standard Schlenk techniques, unless otherwise stated. Reactions 8-11 were performed in tightly capped vials flushed with nitrogen. ¹H and ¹³C NMR chemical shifts are relative to TMS. Mass Spectra were collected on a Finnigan TSQ 7000 Spectrometer and LC-MS data were obtained on an Agilent 1100 ESI-MS system.

General procedure for Cp*RuCl(PPh₃)₂ catalyzed cycloadditions. A mixture of azide, alkyne and Cp*RuCl(PPh₃)₂ in organic solvent (8-20 mL, 0.07–0.2M in reactants) was stirred at a given temperature for a period of time indicated in the Table 1. The progress of the reaction was monitored by ¹H NMR or GC. In most cases the azide was completely consumed at the end of the reaction. The solvent was removed under vacuum and the product was purified by silica gel chromatography. The unreacted alkyne and traces of side products were first eluted out with hexane, followed by 1/1 hexane/ether. The pure 1,5-disubstituted triazole product was then obtained by elution with ether or chloroform.


1-benzyl-5-phenyl-1H-1,2,3-triazole (1a).



- (a) Benzylazide (0.400 g, 3.00 mmol), phenylacetylene (0.500 mL, 4.55 mmol), $\text{Cp}^*\text{RuCl}(\text{PPh}_3)_2$ (25 mg, 0.031 mmol). Solvent, benzene; reaction temperature, 80 °C, reaction time, 2 h; yield, 0.56 g (80%).
- (b) Benzylazide (0.200 g, 1.50 mmol), phenylacetylene (0.300 mL, 2.73 mmol), $\text{Cp}^*\text{RuCl}(\text{PPh}_3)_2$ (25 mg, 0.031 mmol). Solvent, tetrahydrofuran; reaction temperature, 65 °C; reaction time, 3 h; yield, 0.26 g (74%).
- (c) Benzylazide (0.100 g, 0.751 mmol), phenylacetylene (0.150 mL, 1.37 mmol), $\text{Cp}^*\text{RuCl}(\text{PPh}_3)_2$ (30 mg, 0.038 mmol). Solvent, benzene; reaction temperature, r.t.; reaction time, 24 h; yield, 0.13 g (75%).

^1H NMR (CDCl_3): δ 5.54 (s, 2H), 7.07 (t, 2H, $J = 3.6$ Hz), 7.23 – 7.27 (m, 5H), 7.37 – 7.46 (m, 3H), 7.73 (s, 1H). ^{13}C NMR (CDCl_3): δ 51.85, 126.93, 127.22, 128.22, 128.92, 129.08, 129.64, 133.26, 133.34, 135.66, 138.26. EI-MS: m/z 236 $[\text{M} + 1]$.


1-benzyl-5-(2-naphthyl)-1H-1,2,3-triazole (2a)



Benzylazide (0.400 g, 3.00 mmol), 2-ethynylnaphthalene (0.503 g, 3.31 mmol), $\text{Cp}^*\text{RuCl}(\text{PPh}_3)_2$ (25 mg, 0.031 mmol). Solvent, benzene; reaction temperature, 80 °C; reaction time, 4 h; yield, 0.80 g (93%).

^1H NMR (CDCl_3): δ = 5.55 (s, 2H), 7.10 (t, 2H, $J = 3.6$ Hz), 7.24 – 7.33 (m, 4H), 7.47 – 7.54 (m, 2H), 7.68 – 7.74 (m, 2H), 7.83 (t, 3H, $J = 7.35$ Hz). ^{13}C NMR (CDCl_3): δ 52.06, 124.21, 125.93, 125.98, 127.16, 127.34, 127.42, 127.96, 128.32, 128.65, 128.72, 128.99, 133.03, 133.38, 133.57, 133.64, 135.81, 138.34. EI-MS: m/z 285 $[\text{M}^+]$.

1-benzyl-5-butyl-1H-1,2,3-triazole (3a).




Benzylazide (0.340 g, 2.55 mmol), 1-hexyne (0.580 ml, 5.05 mmol), $\text{Cp}^*\text{RuCl}(\text{PPh}_3)_2$ (50 mg, 0.063 mmol). Solvent, benzene; reaction temperature, 80 °C; reaction time, 3 h; yield, 0.45 g (82%).

^1H NMR (CDCl_3): δ = 0.768 (t, 3H, J = 7.2 Hz), 1.15 – 1.27 (m, 2H), 1.36 – 1.46, (m, 2H), 2.44 (t, 2H, J = 7.8 Hz), 5.41 (s, 2H), 7.07 (t, 2H, J = 3.8 Hz), 7.18 – 7.27 (m, 3H), 7.39 (s, 1H). ^{13}C NMR (CDCl_3): δ 14.16, 22.69, 23.35, 30.42, 52.13, 127.62, 128.78, 129.46, 133.05, 133.11, 135.63, 137.99. EI-MS: m/z 216 $[\text{M}+1]$.

1-benzyl-5-(*tert*-butyl)-1H-1,2,3-triazole (4a).


.



Benzylazide (0.400 g, 3.00 mmol), 3,3-dimethyl-1-butyne (0.556 ml, 4.51 mmol), $\text{Cp}^*\text{RuCl}(\text{PPh}_3)_2$ (50 mg, 0.063 mmol). Solvent, benzene; reaction temperature, 80 °C; reaction time, 4 h; yield, 0.54 g (83%).

^1H NMR (CDCl_3): δ = 0.974 (s, 9H), 5.42 (s, 2H), 6.77 (d, 2H, J = 7.0 Hz), 6.87 – 7.00 (m, 3H), 7.14 (s, 1H). ^{13}C NMR (CDCl_3): δ 29.72, 29.99, 52.60, 126.32, 127.68, 128.61, 131.26, 131.37, 136.37, 146.00. EI-MS: m/z 216 $[\text{M}+1]$.


4-(1-benzyl-1H-1,2,3-triazol-5-yl)benzaldehyde (5a).



Benzylazide (0.200 g, 1.50 mmol), 4-ethynylbenzaldehyde (0.200 g, 1.54 mmol), $\text{Cp}^*\text{RuCl}(\text{PPh}_3)_2$ (25 mg, 0.031 mmol). Solvent, benzene; reaction temperature, 80 °C; reaction time, 2 h; yield, 0.32 g (81%).

^1H NMR (CDCl_3): δ 5.59 (s, 2H), 7.06 (t, 2H, $J = 3.3$ Hz), 7.27 (dd, 4H, $J = 3.1$ Hz), 7.43 (d, 2H, $J = 8$ Hz), 7.81 (s, 1H), 7.91 (d, 2H, 8.2 Hz), 10.05 (s, 1H). ^{13}C NMR (CDCl_3): δ 52.33, 127.13, 128.52, 129.08, 129.48, 129.54, 130.20, 132.84, 133.91, 133.98, 135.17, 136.76, 137.04. EI-MS: m/z 264 $[\text{M}+1]$.


2-(1-benzyl-1H-1,2,3-triazol-5-yl)propan-2-ol (6a).



Benzylazide (0.400 g, 3.00 mmol), 2-methyl-3-butyn-2-ol (0.290 ml, 3.00 mmol), $\text{Cp}^*\text{RuCl}(\text{PPh}_3)_2$ (25 mg, 0.031 mmol). Solvent, benzene; reaction temperature, 80 °C; reaction time, 2.5 h; yield, 0.63 g (96%).

^1H NMR (CDCl_3): δ 1.43 (s, 6H), 5.23 (s, 1H), 5.74 (s, 2H), 7.11 – 7.26 (m, 6H). ^{13}C NMR (CDCl_3): δ 30.90, 52.94, 67.63, 127.82, 128.15, 128.91, 130.58, 130.66, 136.62, 144.16. EI-MS: m/z 218 $[\text{M}+1]$.

(1-benzyl-1H-1,2,3-triazol-5-yl)diphenylmethanol (7a).




(a) Benzylazide (0.400 g, 3.00 mmol), 1,1-diphenyl-2-propyn-1-ol (0.688 g, 3.31 mmol), $\text{Cp}^*\text{RuCl}(\text{PPh}_3)_2$ (25 mg, 0.031 mmol). Solvent, benzene; reaction temperature, 80 °C; reaction time, 4 h; yield, 0.89 g (87%).

(b) Benzylazide (0.200 g, 1.50 mmol), 1,1-diphenyl-2-propyn-1-ol (0.344 g, 1.65 mmol), $\text{Cp}^*\text{RuCl}(\text{PPh}_3)_2$ (60 mg, 0.75 mmol). Solvent, benzene; reaction temperature, r.t.; reaction time, 24 h; yield, 0.43 g (83%).

(c) Benzylazide (0.200 g, 1.50 mmol), 1,1-diphenyl-2-propyn-1-ol (0.344 g, 1.65 mmol), Cp*RuCl(PPh₃)₂ (12 mg, 0.015 mmol). Solvent, benzene; reaction temperature, 80 °C; reaction time, 4 h; yield, 0.39 g (75%). The reaction was performed under air.


¹H NMR (CDCl₃): δ 4.14 (s, 1H), 5.36 (s, 2H), 6.82 (s, 1H), 7.02 – 7.05 (m, 2H), 7.13 – 7.30 (m, 13H). ¹³C NMR (CDCl₃): δ 53.04, 127.00, 127.88, 128.17, 128.42, 134.92, 135.01, 135.32, 142.34, 143.94. EI-MS: m/z 342 [M+1].

1-phenethyl-5-phenyl-1H-1,2,3-triazole (8a)




Phenethyl azide (148 mg, 1 mmol), phenylacetylene (113 mg, 1.1 mmol), Cp*RuCl(PPh₃)₂ (8 mg, 0.01 mmol, 1 mol%). Solvent: THF, 10 mL, 60 °C, 2 h. Off-white product obtained in 89% yield (221 mg). ¹H NMR (DMSO- *d*₆): δ 4.31 (t, J = 8.1 Hz, 2H), 5.52 (t, J = 8.1 Hz, 2H), 7.09 (m, 2H), 7.21 – 7.29 (m, 5H), 7.37 – 7.46 (m, 3H), 7.71 (s, 1H). ¹³C NMR (DMSO- *d*₆): δ 36.6, 57.3, 127.0, 127.2, 128.6, 128.9, 129.3, 129.7, 133.42, 133.49, 137.6, 139.3. ESI-MS: m/z 250, [M+H].

3-(5-phenyl-1H-1,2,3-triazol-1-yl)propan-1-ol (9a).




3-Azidopropanol (101 mg, 1 mmol), phenylacetylene (113 mg, 1.1 mmol), Cp*RuCl(PPh₃)₂ (8 mg, 0.01 mmol, 1 mol%). Solvent: THF, 10 mL, 60 °C, 2 h. White microcrystalline product obtained in 82% yield (167 mg). ¹H NMR (DMSO- *d*₆): δ 1.91 (m, 2H), 3.53 (t, J = 7.1 Hz, 2H), 3.81 (t, J = 8.2 Hz, 2H), 7.22 – 7.36 (m, 5H), 7.67 (s, 1H). ¹³C NMR (DMSO- *d*₆): δ 31.1, 45.5, 61.2, 127.5, 129.4, 128.6, 129.1, 133.3, 142.2. ESI-MS: m/z 204, [M+H].

3-(1-phenethyl-1H-1,2,3-triazol-5-yl)pyridine (10a)




Phenethyl azide (148 mg, 1 mmol), 3-propynyl pyridine (111 mg, 1.1 mmol), $\text{Cp}^*\text{RuCl}(\text{PPh}_3)_2$ (8 mg, 0.02 mmol, 2 mol%). Solvent: dioxane, 10 mL, 60°C, 12 h. Product obtained as off-white powder in 80% yield (200 mg). ^1H NMR (CDCl_3): δ = 3.23 (t, 2H, J = 6.7 Hz), 4.56 (t, 2H, J = 6.7 Hz), 6.84 (d, 2H), 7.21 (m, 3H), 7.30 (m, 1H), 7.42 (m, 1H), 7.69 (s, 1H), 8.22 (s, 1H), 8.69 (br. s, 1H). ^{13}C NMR (CDCl_3): δ 36.5, 49.4, 122.9, 123.4, 126.9, 128.53, 128.59, 133.2, 135.0, 136.0, 136.6, 148.9, 150.1. ESI-MS: m/z 251, $[\text{M}+\text{H}]$.

1-(1-(4-methoxyphenyl)-1H-1,2,3-triazol-5-yl)cyclohexanol (11a)



4-Azido anisole (149 mg, 1 mmol), 1-ethynylcyclohexanol (136 mg, 1.1mmol), $\text{Cp}^*\text{RuCl}(\text{PPh}_3)_2$ (16 mg, 0.02 mmol, 2 mol%). Solvent: dioxane, 10 mL, 60°C, 6 h. Slightly yellow product obtained in 94% yield (257mg). ^1H NMR (CDCl_3): δ = 1.24 (m, 1H), 1.46-1.59 (m, 5H), 1.79 (m, 4H), 2.49 (br. s, 1H), 3.89 (s, 3H), 6.9 (d, 2H, J = 7.2 Hz), 7.43 (d, 2H, J = 7.2 Hz), 7.63 (s, 1H). ^{13}C NMR (CDCl_3): δ 21.6, 25.0, 37.1, 55.6, 68.8, 114.0, 128.5, 130.5, 131.1, 144.5, 160.5. ESI-MS: m/z 274, $[\text{M}+\text{H}]$.

1-benzyl-4,5-diphenyl-1H-1,2,3-triazole (12).



Benzylazide (0.400 g, 3.00 mmol), diphenylacetylene (0.588 g, 3.30 mmol), $\text{Cp}^*\text{RuCl}(\text{PPh}_3)_2$ (25 mg, 0.031 mmol). Solvent, benzene; reaction temperature, 80 °C; reaction time, 2 h; yield, 0.75 g (80 %).


^1H NMR (CDCl_3): δ = 5.41 (s, 2H), 7.02 (t, 2H, J = 3.5 Hz), 7.13 – 7.16 (m, 2H), 7.24 – 7.26 (m, 7H), 7.39 – 7.44 (m, 3H), 7.46 – 7.58 (m, 2H). ^{13}C NMR (CDCl_3): δ 52.15, 126.83, 127.61, 127.80, 127.98, 128.26, 128.56, 128.81, 129.29, 129.80, 130.22, 131.05, 134.00, 135.49, 144.64. EI-MS: m/z 312 $[\text{M}+1]$.

$\text{Ru}(\text{OAc})_2(\text{PPh}_3)_2$ catalyzed reactions. A mixture of benzylazide, phenylacetylene and $\text{Ru}(\text{OAc})_2(\text{PPh}_3)_2$ was refluxed in 20 mL of benzene for 4 h. The progress of the reaction was monitored by ^1H NMR. The azide was consumed completely at the end of the reaction, as confirmed by NMR. The solvent was removed under reduced pressure and the product was purified by silica gel column chromatography. The unreacted phenylacetylene and the side products were first eluted out with hexane, and 2/1 hexane/ether. The pure 1,4-substituted triazole was then obtained by elution with 1/1 hexane/ether.


$\text{CpRu}(\text{PPh}_3)_2\text{Cl}$ catalyzed reactions. A mixture of benzylazide (0.200 g, 1.50 mmol), phenylacetylene (0.250 mL, 2.25 mmol) and $\text{CpRu}(\text{PPh}_3)_2\text{Cl}$ (54.54 mg, 0.0751 mmol) was refluxed in 20 mL of benzene for 8 h. The progress of the reaction was monitored by ^1H NMR. The azide was consumed completely at the end of the reaction, as confirmed by NMR. The solvent was removed under vacuum and the product was purified by silica gel column chromatography. The unreacted phenylacetylene and the side products were first eluted out with hexane, and 2/1 hexane/ether. The 1:5.8 mixed 1,4-/1,5- disubstituted triazoles were then obtained by elution with 1/1 hexane/ether.

Selected NMR spectra of 1, 5- and 1,4-disubstituted triazoles.


The ^1H NMR spectrum of **1a** in CDCl_3 .





The ^{13}C NMR spectrum of **1a** in CDCl_3 .




The ^1H NMR spectrum of **2a** in CDCl_3 .





The ^{13}C NMR spectrum of **2a** in CDCl_3 .




The ^1H NMR spectrum of **3a** in CDCl_3 .





The ^{13}C NMR spectrum of **3a** in CDCl_3 .




The ^1H NMR spectrum of **4a** in CDCl_3 .





The ^{13}C NMR spectrum of **4a** in CDCl_3 .





The ^1H NMR spectrum of **5a** in CDCl_3 .





The ^{13}C NMR spectrum of **5a** in CDCl_3 .




The ^1H NMR spectrum of **6a** in CDCl_3 .





The ^{13}C NMR spectrum of **6a** in CDCl_3 .




The ^1H NMR spectrum of **7a** in CDCl_3 .




The ^{13}C NMR spectrum of **7a** in CDCl_3 .




The ^1H NMR spectrum of **12** in CDCl_3 .





The ^{13}C NMR spectrum of **12** in CDCl_3 .





The ^1H NMR spectrum of **1b** in CDCl_3 .





The ^{13}C NMR spectrum of **1b** in CDCl_3 .




The ^1H NMR spectrum of **2b** in CDCl_3 .





The ^{13}C NMR spectrum of **2b** in CDCl_3 .




The ^1H NMR spectrum of **3b** in CDCl_3 .





The ^{13}C NMR spectrum of **3b** in CDCl_3 .




The ^1H NMR spectrum of **4b** in CDCl_3 .




The ^{13}C NMR spectrum of **4b** in CDCl_3 .





The ^1H NMR spectrum of **6b** in CDCl_3 .




The ^1H NMR spectrum of **7b** in CDCl_3 .




The ^{13}C NMR spectrum of **7b** in CDCl_3 .




The X-ray structure of **1a**.

zhli6

The X-ray structure of **6a**.

zhli3

The X-ray structure of **7a**.

zhli5

The X-ray structure of **12**.